204 related articles for article (PubMed ID: 35223723)
1. Metabolic Phenotyping Predicts Gemcitabine and Cisplatin Chemosensitivity in Patients With Cholangiocarcinoma.
Suksawat M; Phetcharaburanin J; Klanrit P; Namwat N; Khuntikeo N; Titapun A; Jarearnrat A; Vilayhong V; Sa-Ngiamwibool P; Techasen A; Wangwiwatsin A; Mahalapbutr P; Li JV; Loilome W
Front Public Health; 2022; 10():766023. PubMed ID: 35223723
[TBL] [Abstract][Full Text] [Related]
2. In vitro and molecular chemosensitivity in human cholangiocarcinoma tissues.
Suksawat M; Klanrit P; Phetcharaburanin J; Namwat N; Khuntikeo N; Titapun A; Jarearnrat A; Sa-Ngiamwibool P; Techasen A; Loilome W
PLoS One; 2019; 14(9):e0222140. PubMed ID: 31504065
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment.
Ishimoto U; Kondo S; Ohba A; Sasaki M; Sakamoto Y; Morizane C; Ueno H; Okusaka T
Oncology; 2018; 94(2):72-78. PubMed ID: 29017161
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapeutic resistant cholangiocarcinoma displayed distinct intratumoral microbial composition and metabolic profiles.
Sitthirak S; Suksawat M; Phetcharaburanin J; Wangwiwatsin A; Klanrit P; Namwat N; Khuntikeo N; Titapun A; Jarearnrat A; Sangkhamanon S; Loilome W
PeerJ; 2022; 10():e13876. PubMed ID: 35990899
[TBL] [Abstract][Full Text] [Related]
5. Plasmalemma vesicle-associated protein promotes angiogenesis in cholangiocarcinoma via the DKK1/CKAP4/PI3K signaling pathway.
Wang Y; Yu H; Xie X; Deng T; Ye L; Wu L; Ding X; Yang Z; Zhu Q; Li J; Zheng Y; Yu Z; Chen G
Oncogene; 2021 Jun; 40(25):4324-4337. PubMed ID: 34079085
[TBL] [Abstract][Full Text] [Related]
6. Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma.
Asukai K; Kawamoto K; Eguchi H; Konno M; Asai A; Iwagami Y; Yamada D; Asaoka T; Noda T; Wada H; Gotoh K; Nishida N; Satoh T; Doki Y; Mori M; Ishii H
Ann Surg Oncol; 2017 Aug; 24(8):2344-2352. PubMed ID: 28560603
[TBL] [Abstract][Full Text] [Related]
7. Case report: A report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy.
Zhang X; Tang H; Fan J; Wang R; Han Y; Su S; Gan Y; Peng F; Rao M; Zhang J; Li B; Yang X
Front Immunol; 2022; 13():1051130. PubMed ID: 36618353
[TBL] [Abstract][Full Text] [Related]
8. Intrahepatic cholangiocarcinoma with sarcomatous change producing granulocyte-colony stimulating factor.
Takenaka M; Akiba J; Kawaguchi T; Niizeki T; Arinaga-Hino T; Sata M; Nakashima O; Yano H; Kage M
Pathol Int; 2013 Apr; 63(4):233-5. PubMed ID: 23692426
[No Abstract] [Full Text] [Related]
9. Serum thrombospondin-1 serves as a novel biomarker and agonist of gemcitabine-based chemotherapy in intrahepatic cholangiocarcinoma.
Ding DY; Gan XJ; Zhang JN; Hou GJ; Tao QF; Sun DP; Li W; Yang Y; Ding WB; Yu J; Liu L; Yang F; Zhou WP; Yuan SX
Br J Cancer; 2023 Mar; 128(5):907-917. PubMed ID: 36526676
[TBL] [Abstract][Full Text] [Related]
10. Enhanced expression of ten-eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P-glycoprotein expression.
Wang C; Ye H; Zhang L; Cheng Y; Xu S; Zhang P; Zhang Z; Bai J; Meng F; Zhong L; Shi G; Li H
Cancer Med; 2019 Mar; 8(3):990-1003. PubMed ID: 30784212
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis.
Lu M; Qin X; Zhou Y; Li G; Liu Z; Geng X; Yue H
Cell Death Dis; 2021 Jan; 12(1):72. PubMed ID: 33436545
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases.
Lee MA; Woo IS; Kang JH; Hong YS; Lee KS
Jpn J Clin Oncol; 2004 Sep; 34(9):547-50. PubMed ID: 15466829
[TBL] [Abstract][Full Text] [Related]
13. Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma.
Charoentum C; Thongprasert S; Chewaskulyong B; Munprakan S
World J Gastroenterol; 2007 May; 13(20):2852-4. PubMed ID: 17569122
[TBL] [Abstract][Full Text] [Related]
14. Blockade of chloride channel-3 enhances cisplatin sensitivity of cholangiocarcinoma cells though inhibiting autophagy.
Han Y; Zhou Y; Zhou L; Jia X; Yu X; An X; Shi Z
Can J Physiol Pharmacol; 2022 Jul; 100(7):584-593. PubMed ID: 35413227
[TBL] [Abstract][Full Text] [Related]
15. Combination of anti-L1 cell adhesion molecule antibody and gemcitabine or cisplatin improves the therapeutic response of intrahepatic cholangiocarcinoma.
Cho S; Lee TS; Song IH; Kim AR; Lee YJ; Kim H; Hwang H; Jeong MS; Kang SG; Hong HJ
PLoS One; 2017; 12(2):e0170078. PubMed ID: 28166242
[TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma.
Lee GW; Kang JH; Kim HG; Lee JS; Lee JS; Jang JS
Am J Clin Oncol; 2006 Apr; 29(2):127-31. PubMed ID: 16601429
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S
Life Sci; 2022 May; 296():120427. PubMed ID: 35218764
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells.
Kitagawa K; Moriya K; Kaji K; Saikawa S; Sato S; Nishimura N; Namisaki T; Akahane T; Mitoro A; Yoshiji H
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066548
[TBL] [Abstract][Full Text] [Related]
19.
Treeriya R; Ho PN; Titapun A; Klanrit P; Suksawat M; Kulthawatsiri T; Sirirattanakul S; Loilome W; Namwat N; Wangwiwatsin A; Chamadol N; Khuntikeo N; Phetcharaburanin J
PeerJ; 2023; 11():e15386. PubMed ID: 37187520
[TBL] [Abstract][Full Text] [Related]
20. GDC-0980 (apitolisib) treatment with gemcitabine and/or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K/Akt/mTOR pathway.
Jang DK; Lee YG; Chan Chae Y; Lee JK; Paik WH; Lee SH; Kim YT; Ryu JK
Biochem Biophys Res Commun; 2020 Sep; 529(4):1242-1248. PubMed ID: 32819590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
